drug pricing
Social Security Finance Bill 2016 in France: French Government Looks To Make 50% Of Healthcare Savings Through Drug Price Cuts
November 24 by Emilie ChrivWith there being a 12.8 million Euro deficit in France’s 2015 budget, the French government announced on 24 th September plans for the Projet de Loi de Financement de la Sécurité Sociale 2016 (PLFSS;...
Social Security Finance Bill 2016 in France: French Government Looks To Make 50% Of Healthcare Savings Through Drug Price Cuts
November 23 by Dr Steven BradshawWith there being a 12.8 million Euro deficit in France’s 2015 budget, the French government announced on 24th September plans for the Projet de Loi de Financement de la Sécurité Sociale 2016 (PLFSS; S...
5 Things I Learned at Pharma Times’ PPRS Meeting
March 07 by Gerald ClarkeOn the 26thof February, I attended PharmaTimes’ PPRS and Value Based Assessment meeting. It was an eye opening experience to the depth of feeling being expressed around the UK government&rsquo...
The 4 Biggest Battles in Drug Pricing
May 10 by Gerald ClarkeThe global financial atmosphere in the past years has catalysed many changes in the relationship between the pharma industry and governments. In a fiscally constrained environment it is unsurprising...
Portuguese Hospitals Block Access to New Medicines as Retail Drug Sector Expected to Meet Savings Goal
September 29 by Tania Rodrigues, an analyst at IHS Global InsightAccess to expensive medicines is becoming increasingly difficult in Portuguese public hospitals, while savings with retail pharmacy expenditure are expected to be better than projections in the Memora...
Are Orphan Drugs Still a Licence to Print Money?
July 20 by Andrea CharlesIn this podcast Donald Macarthur, global pharmaceutical business analyst, speaks to Andrea Charles from Pharma IQ, about Pharma's steps into the orphan drug market and whether payers can afford to fun...
Health Technology Assessment: Developing Strategies for Understanding Value-Based Pricing
January 19 by Pharma IQValue-based pricing is one issue which divides those in the pharmaceutical industry and the medical community. Much of this debate centres around how value is defined. This is a subject which has...
Trying to Stay Cool: Canadian Pharmacy Players Under Pressure from Changes to Generic Pricing
December 08 by Pharma IQJoe Knott, Managing Director of the Pangaea Group, joined Andrea Charles from Pharma IQ, to discuss the dramatic changes to the Canadian drug distribution market in recent years. Knott sha...
Health Technology Assessment Climbs Up the European Agenda due to Lack of Resources
November 03 by Andrea CharlesHealth Technology Assessment (HTA) is climbing up the agenda in many European countries due to increasing healthcare costs and budgetary pressures. Limited resource According to the European Society...